ElectromeElectrome home
Buy ActiPatch®
Electrome · Evidence

Postoperative Recovery

Post-surgical pain, edema, and recovery outcomes across cesarean, plastic-surgery, and post-amputation populations.

publication

Meta-analysis of Clinical Efficacy of Pulsed Radio Frequency Energy Treatment

Synthesis of clinical PRFE evidence across postoperative recovery, chronic pain, wound healing, and musculoskeletal indications.

View source
publication

Control of Postoperative Pain with a Wearable Continuously Operating Pulsed Radiofrequency Energy Device: A Preliminary Study

Randomized active-versus-placebo pilot in 18 women following breast augmentation; active treatment associated with lower VAS pain and reduced analgesic use over 7 days.

View source
publication

Effects of Pulsed Electromagnetic Fields on Postoperative Pain: A Double-Blind Randomized Pilot Study in Breast Augmentation Patients

Postoperative PEMF evaluation following breast augmentation, with pain, analgesic-use, and patient-reported recovery endpoints.

View source
publication

Pulsed Electromagnetic Fields for Postsurgical Pain Management in Women Undergoing Cesarean Section: A Randomized, Double-Blind, Placebo-Controlled Trial

Randomized placebo-controlled trial reporting significant reductions in post-cesarean pain, analgesic use, wound edema and exudate with PEMF therapy.

View source
publication

Treating Intractable Postamputation Pain with Noninvasive, Wearable, Nonthermal, Pulsed Shortwave (Radiofrequency) Therapy: A 12-Patient Case Series

12-patient case series describing wearable pulsed shortwave therapy for difficult-to-treat phantom and residual limb pain.

View source
Educational summary only. Not medical advice. Individual results vary. Consult a qualified healthcare provider before making treatment decisions. ActiPatch® is FDA-cleared (K192234) for musculoskeletal pain; RecoveryRx® is FDA-cleared (K190251) for adjunctive treatment of postoperative pain. Study outcomes such as edema reduction are evidence findings, not additional cleared indications. Both devices are developed and manufactured by BioElectronics Corporation and marketed by Electrome under an exclusive license.